Portfolio company, Oxford BioTherapeutics has expanded its partnership with Boehringer Ingelheim to do more to target difficult-to-reach cancers and deliver best in class treatment for cancer patients.
Portfolio company, Oxford BioTherapeutics has expanded its partnership with Boehringer Ingelheim to do more to target difficult-to-reach cancers and deliver best in class treatment for cancer patients.
Estimated reading time: 2 min
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
If you are interested in learning more about how to protect yourself, visit the FCA’s website here.